Alcon takes a crack at multibillion-dollar dry eye market, picks up 2 drugs from Langer spinout
Kala Pharmaceuticals may have never come close to the blockbuster dreams it had for its dry eye disease treatment, but Alcon wants to see if it can take the drug further.
After giving commercialization its best shot over the past few years, Kala decided the marketing game is not for it after all. Instead, it will sell both of its commercial eye drop products — Eysuvis for dry eye disease, and Inveltys for post-operative inflammation and pain following ocular surgery — to Alcon for $60 million in cash, plus an undisclosed amount of milestones.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 164,000+ biopharma pros reading Endpoints daily — and it's free.